The use of a paclitaxel eluting balloon in small vessels

Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020

The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. 

The aim of this study was to evaluate the efficacy of paclitaxel-eluting balloons (PEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels. This multicenter and prospective study randomized 182 patients with lesions in small vessels (reference diameter <2.8 mm) to receive a paclitaxel eluting balloon and provisional conventional stent (n = 90) or a paclitaxel-eluting stent. 

The primary endpoint of non-inferiority was late lumen loss with a delta of 0.25 mm. Secondary end points were binary restenosis, TLR and MACE, (death, myocardial infarction and revascularization), at 6 months. Both groups were well balanced except for the smallest diameter in PEB-treated vessels, (2.15 ± 0.27 mm vs. 2.25 ± 0.24 mm, p = 0.003). 20% of the PEB group required a conventional stent rescue after dilation. 

The primary end point was significantly lower with PEB compared with PES, (0.08 ± 0.38 mm vs. 0.29 ± 0.44 mm, p for noninferiority <0.001, p for superiority = 0.001). At 6 months both were similar in binary restenosis, (PEB 8.9% versus PES 14.1%, P = 0.25), TLR, (PEB 4.4% versus PES 7.6%, p = 0.37), and MACE, (PEB 7.8% versus DES 13.2%, P = 0.77).

Conclusion 

Small-vessel angioplasty using PEB had a lower late lumen loss with similar restenosis and revascularization than paclitaxel-eluting stents at 6 months.

Editorial Comment:

The results are promising, especially considering that the average size of the vessels was <2.5 mm. It would be very interesting to track this in a longer-term study and with a primary clinical purpose as well as a comparison against edge limus eluting stents.

SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....